CANVAS – Canagliflozin a kardiovaskulární a renální vliv u diabetes mellitus 2. Typu
| Authors | |
|---|---|
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.kardiologickarevue.cz/casopisy/kardiologicka-revue/2019-1-12/canvas-canagliflozin-a-kardiovaskularni-a-renalni-vliv-u-diabetes-mellitus-2-typu-109103 |
| Keywords | Canagliflozin; Cardiovascular and renal safety; Programme CANVAS; Type 2 diabetes mellitus |
| Description | Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycaemia as well as blood pressure, body weight, and albuminuria in people with diabetes. The CANVAS Programme integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Conclusions: In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a significantly lower risk of cardiovascular events than those who received placebo. A boundary higher risk of amputation, primarily at the level of the toe or metatarsus was observed in the study. These complications, however, were not proved in subsequent observational databases. © 2019, Ambit Media a.s.. All rights reserved. |